中国医药科学Issue(17)：147-149,3.
儿童急性髓系白血病实施阿糖胞苷冲击大剂量疗法的安全性探析
An analysis of the safety of cytarabine high-dose therapy in the treatment of acute myelogenous leukemia for children patients
丁百全 1荆强2
作者信息
- 1. 济南市儿童医院静配科，山东济南 250021
- 2. 济南市第四人民医院药剂科，山东济南 250000
- 折叠
摘要
Abstract
Objective To explore the safety of cytarabine high-dose therapy in the treatment of acute myelogenous leukemia for children patients,so as to provide guidance for clinical drug use.MethodsTwo groups all received chemotherapy of DA.The dosage of cytarabine in clinical group A was 3g/m2,and the dosage in clinical group B was 2g/m2.Symptoms alleviation,damages of nervous system and other toxic and adverse effects were compared between the two groups. ResultsConditions of anemia,bleeding and leukocyte infiltration in clinical group A were significantly minor than those in clinical group B,and the difference of infections in the two groups was not significant.Damages of nervous system such as headache,somnolence, dullness,attention lapses and convulsion in clinical group A were significantly severer than those in clinical group B.Toxic and adverse effects such as nystagmus,dysdiadochokinesia and ataxia in clinical group A were significantly severer than those in clinical group B.ConclusionCytarabine high-dose therapy in the treatment of acute myelogenous leukemia for children patients is effective in improving clinical efficacy,but its toxic and adverse effects are severe.关键词
急性髓系白血病/阿糖胞苷/安全性Key words
Acute myelogenous leukemia/Cytarabine/Safety分类
医药卫生引用本文复制引用
丁百全,荆强..儿童急性髓系白血病实施阿糖胞苷冲击大剂量疗法的安全性探析[J].中国医药科学,2014,(17):147-149,3.
